How much does Tebentafusp-tebn cost?

Tebentafusp-tebn, trade nameKimmtrak, is an anticancer drug used to treat uveal melanoma (eye cancer). Tibenforsi is clinically a bispecificgp100 peptide-HLA-guided CD3 T cell conjugate that will be administered via intravenous infusion and was approved for medical use in the United States in January 2022.

Tebenforx is a novel immunotherapy that causes cytotoxicity in cancer cells. During the first three doses, tebenforxide increased serum levels of cytokines (IFN-γ, TNFα, IL-2, IL-6, IL-10, and IL-1RA) and chemokines (CXCL9, CXCL10, CXCL11, hepatocyte growth factor, and monocyte chemoattractant protein-1). Cytokine and chemokine levels peaked between 8 and 24 hours after treatment, with levels returning to baseline before subsequent doses. In subsequent treatment cycles, fewer patients experienced cytokine elevations and at a lower intensity than during the first three doses. Tebenforx also reduced lymphocyte counts after the first three doses and returned to baseline before subsequent doses. In a phase III clinical trial, patients treated with tembrolizumab had better overall survival rates compared with pembrolizumab, ipilimumab, or dacarbazine.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.